TABLE 2.
Estimates of the two‐sample MR analyses for causal associations between MDD and overall breast cancer risk
| Outcomes | SNPs | Participants N (case/control) | MR estimates, per log‐odds ratio increment of MDD | Pleiotropy effects | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IVW | Weighted median | MR‐PRESSO corrected | MR‐Egger regression Intercept | ||||||||
| OR (95% CI) | P‐value | P‐heter | OR (95% CI) | P‐value | OR (95% CI) | P‐value | Intercept (SE) | P‐value | |||
| Breast cancer | 92 | 228,951 (122,977/105,974) | 1.087 (1.011–1.170) | 0.025 | < 0.001 | 1.091 (1.002–1.189) | 0.046 | 1.090 (1.017–1.168) | 0.016 | −0.0004 (0.006) | 0.946 |
| ER+ Breast cancer | 92 | 175,475 (69,501/105,974) | 1.059 (0.969–1.157) | 0.208 | < 0.001 | 1.049 (0.945–1.165) | 0.367 | 1.059 (0.974–1.152) | 0.179 | −0.0036 (0.0069) | 0.599 |
| ER‐ Breast cancer | 92 | 127,442 (21,468/105,974) | 1.163 (0.994–1.361) | 0.060 | 0.303 | 1.100 (0.989–1.224) | 0.078 | 1.101 (0.990–1.224) | 0.081 | 0.000 (0.008) | 0.991 |
Abbreviations: 95% CI, 95% confidential interval; ER, estrogen receptor; IVW, inverse variance weighted; MR, Mendelian Randomization; MR‐PRESSO, MR‐pleiotropy residual sum and outlier; OR, odds ratio; P‐heter, P‐heterogneity; SE, standard error; SNP, single‐nucleotide polymorphism.